Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rotigotine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 12/20 | 0.98 |
| ▸ | DRD3 known ✓ | P35462 | 9/20 | 0.98 |
| ▸ | DRD4 known ✓ | P21917 | 7/20 | 0.98 |
| ▸ | DRD1 | P21728 | 5/20 | 0.98 |
| ▸ | HTR1A | P08908 | 2/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | CNR1 | P21554 | 1/20 | 0.98 |
| ▸ | ACHE | P22303 | 1/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.98 |
| ▸ | HTR2A | P28223 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.98 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.98 |
| ▸ | HRH1 | P35367 | 1/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.98 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rotigotine SCHEMBL29483747 | 1.00 | DRD2 (0.98) | DRD2DRD3DRD4DRD1HTR1A | |
| Rotigotine SCHEMBL2597403 | 1.00 | DRD2 (0.98) | DRD2DRD3DRD4DRD1HTR1A | |
| Rotigotine SCHEMBL30730591 | 1.00 | DRD2 (0.98) | DRD2DRD3DRD4DRD1HTR1A | |
| Rotigotine SCHEMBL30200958 | 0.99 | DRD2 (1.00) | DRD2DRD3DRD4DRD1HTR1A | |
| Rotigotine SCHEMBL1088585 | 0.99 | DRD2 (1.00) | DRD2DRD3DRD4DRD1HTR1A | |
| Rotigotine SCHEMBL29354493 | 0.99 | DRD2 (1.00) | DRD2DRD3DRD4DRD1HTR1A | |
| Rotigotine SCHEMBL9405994 | 0.99 | DRD2 (1.00) | DRD2DRD3DRD4DRD1HTR1A | |
| Rotigotine SCHEMBL50425 | 0.99 | DRD2 (1.00) | DRD2DRD3DRD4DRD1HTR1A | |
| Rotigotine SCHEMBL15970012 | 0.98 | DRD2 (0.98) | DRD2DRD3DRD4DRD1HTR1A | |
| SCHEMBL14696824 | 0.94 | DRD2 (0.89) | DRD2DRD3DRD4DRD1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111393309-B | Preparation method of (S) -1,2,3, 4-tetrahydro-5-methoxy-N-propyl-2-naphthylamine hydrochloride | 上海皓元医药股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-114805095-A | Preparation method of (S) -5-methoxy-1, 2,3, 4-tetrahydro-N-propyl-2-naphthylamine | 上海柏狮生物科技有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-111393309-A | Preparation method of (S) -1,2,3, 4-tetrahydro-5-methoxy-N-propyl-2-naphthylamine hydrochloride | 上海皓元医药股份有限公司 | 2020-07-10 | — | — | CN | disclosed |
| WO-2015186138-A1 | IMPROVED PROCESS FOR THE PREPARATION OF CRYSTALLINE FORM II OF ROTIGOTINE | DAVALURI RAMAMOHAN RAO (IN) | 2015-12-10 | — | — | WO | disclosed |
| US-20110313176-A1 | PROCESSES FOR PREPARING HIGHLY PURE ROTIGOTINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2011-12-22 | — | — | US | disclosed |
| WO-2011146610-A2 | AN ENANTIOSELECTIVE SYNTHESIS OF CHIRAL AMINES FOR THE PRODUCTION OF ROTIGOTINE | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-11-24 | — | — | WO | disclosed |
| WO-2010073124-A2 | PROCESSES FOR PREPARING HIGHLY PURE ROTIGOTINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313176-A1 | PROCESSES FOR PREPARING HIGHLY PURE ROTIGOTINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | MC4R, AVPR2, MC5R | DRD2 100/4885DRD3 216/4885DRD4 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.